1 / 7

Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial

This slide deck summarizes the results of the OPTIMIST-2 Trial, which explored the efficacy of Simeprevir + Sofosbuvir treatment in patients with HCV GT1 and cirrhosis. The study included treatment-naïve and treatment-experienced individuals, and the results showed high sustained virologic response (SVR12) rates.

aeverett
Download Presentation

Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment Naïve and Treatment Experienced Simeprevir+ Sofosbuvir in GT1 with CirrhosisOPTIMIST-2 Trial LawitzE, et al. Hepatology. 2016:64:360-9.

  2. Simeprevir+ Sofosbuvir for HCVGT 1 with CirrhosisOPTIMIST-2 Trial: Study Features Source: Lawitz E, et al. Hepatology. 2016:64:360-9.

  3. Simeprevir+ Sofosbuvir for HCVGT 1 with CirrhosisOPTIMIST-2 Trial: Study Design 0 12 24 Week GT-1 Naïve/Experienced Compensated Cirrhosis Simeprevir+ Sofosbuvir n =103 SVR12 Drug DosingSimeprevir: 150 mg once dailySofosbuvir: 400 mg once daily Source: Lawitz E, et al. Hepatology. 2016:64:360-9.

  4. Simeprevir + Sofosbuvir for HCV GT 1 with CirrhosisOPTIMIST-2 Trial: Results OPTIMIST 2: SVR12, by Treatment Experience 86/103 44/50 42/53 SVR12 = sustained virologic response at 12 weeks Source: Lawitz E, et al. Hepatology. 2016:64:360-9.

  5. Simeprevir + Sofosbuvir for HCV GT 1 with CirrhosisOPTIMIST-2 Trial: Results OPTIMIST 2: SVR12, by Genotype 1 Subtype 60/72 25/34 35/38 26/31 SVR12 = sustained virologic response at 12 weeks Source: Lawitz E, et al. Hepatology. 2016:64:360-9.

  6. Simeprevir + Sofosbuvir for HCV GT 1 with CirrhosisOPTIMIST-2 Trial: Conclusions Source: Lawitz E, et al. Hepatology. 2016:64:360-9.

  7. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related